A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CDX-6114 Following Single, Ascending Oral Dose Administration to Healthy Volunteers
Latest Information Update: 06 Nov 2021
At a glance
- Drugs CDX-6114 (Primary)
- Indications Phenylketonuria
- Focus Adverse reactions
- Sponsors Codexis
- 02 Aug 2021 Status changed from recruiting to completed.
- 26 Mar 2019 Planned End Date changed from 1 Mar 2019 to 11 Apr 2019.
- 26 Mar 2019 Planned primary completion date changed from 1 Feb 2019 to 28 Mar 2019.